Inbiomotion
In.bio.motion is raising the question: did previous trials miss the mark by not pre-selecting the correct women who are at-risk and who would benefit from these treatments ?
In.bio.motion is raising the question: did previous trials miss the mark by not pre-selecting the correct women who are at-risk and who would benefit from these treatments ?
